<DOC>
	<DOCNO>NCT00468728</DOCNO>
	<brief_summary>This comparative study investigate safety efficacy PAR-101/OPT-80 ( fidaxomicin ) versus vancomycin subject Clostridium difficile-associated diarrhea ( CDAD ) .</brief_summary>
	<brief_title>PAR-101/OPT-80 Versus Vancomycin Treatment Clostridium Difficile-Associated Diarrhea ( CDAD )</brief_title>
	<detailed_description>The primary objective pivotal study investigate safety efficacy PAR-101/OPT-80 versus vancomycin subject Clostridium difficile-associated diarrhea ( CDAD ) . The cure rate end therapy recurrence rate evaluate compare .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Clostridium Infections</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Males/females CDAD Females must use adequate contraception Signed informed consent Lifethreatening CDAD Toxic megacolon Pregnant Concurrent use diarrheal agent Participation trial</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>CDAD , Clostridium difficile , diarrhea</keyword>
	<keyword>Clostridium difficile-Associated Diarrhea</keyword>
</DOC>